You are here

Neuro Optical Diagnostic System for Macular Degeneration

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG057250-01
Agency Tracking Number: R41AG057250
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA16-303
Solicitation Year: 2016
Award Year: 2017
Award Start Date (Proposal Award Date): 2017-09-15
Award End Date (Contract End Date): 2019-08-31
Small Business Information
Newton, MA 02459-3605
United States
DUNS: 078739650
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (617) 755-3838
Business Contact
Phone: (617) 755-3838
Research Institution
360 HUNTINGTON AVE, 177-500
BOSTON, MA 02115-5005
United States

 Nonprofit College or University

Age related macular degeneration AMD causes progressive loss of central vision and is the leading
cause of blindness in the developed world A major challenge in the development of effective treatments for AMD
is the lack of sensitive practical visual function endpoints People with AMD manifest delayed dark adaptation
DA recovery and DA tests are a FDA approved method for diagnosing AMD Current DA tests measure
psychophysical thresholds for the detection of visual stimuli following photobleaching to monitor the recovery of
sensitivity over time These tests typically last minutes per eye require sustained attention from the patient
and dedicated light proof test facilities all of which are problematic for clinical testing Rapid protocols address
some of these issues but test only the early stage of DA test only a single retinal location and still require both
eyes to be tested separately There is therefore an unmet need for a rapid practical sensitive and objective test
that will provide quantitative endpoints for early diagnosis and monitoring response to newly developed
Visual evoked potentials VEP generated in response to visual stimuli provide a quantitative objective
measure of the neuro optical pathways and visual processes that do not require sustained attention from the
patient Systematic use of this very attractive technique in the context of DA has been hampered by lack of easy
to administer affordable instrumentation NeuroFieldz and Northeastern University have developed a new
system called NeuroDotVR that combines a high resolution sensor for scalp electric potentials and fields with a
smartphone powered headset and have demonstrated superior sensitivity to visual responses to a variety of
visual stimuli Preliminary results are presented here with VEP responses under DA with healthy subjects In this
Phase I STTR project we propose to optimize the NeuroDotVR product and to test the performance in patients
The project aims are
Specific Aim Develop custom stimuli for Macular DA We will validate measurement approaches
for photobleaches of the macula in healthy young eyes VEPs will be measured with a scotopic flickering
checkerboard stimulus that fills the macula VEP Amplitude will be measured for a flickering checkerboard
pattern of scotopic luminance contrast E binocularly and E dichoptically i e simultaneously and
independently with a different temporal frequency in each eye for frequency tagging We will estimate the time
required for VEP amplitude and latencies to reach dark adapted levels as a function of temporal frequency
Specific Aim Multi focal Macular DA in AMD will validate dichoptic tests developed in Aims and
in patients with early stage AMD patients with intermediate stage AMD and age matched controls The
multifocal stimuli will be divided into locations eyes eccentricities sectors and DA times for each
location will be compared with structural deficits in retinal fundus images PROJECT NARRATIVE
TITLE Neuro Optical Diagnostic System for Macular Degeneration
This project seeks to develop a new portable wireless system called NeuroDotVR that combines a sensor for
measurement of scalp electric potentials and fields during recovery from dark adaptation using visual stimuli
presented by a virtual reality headset powered by a smartphone and to test them in patients with Age related
Macular Degeneration AMD NeuroDotVR will address an unmet need for a practical sensitive test that will
provide quantitative endpoints for early diagnosis and monitoring response to newly developed treatments for

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government